



Biotech Daily

Friday October 4, 2013

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: OPTISCAN UP 13%, AVITA DOWN 8%**
- * **3-MONTH SIRTEX DOSE SALES UP 4%**
- * **CELLMID RECEIVES \$712k R&D TAX REFUND**
- * **HEALTHLINX RAISES \$70k**
- * **CEO ALAN SHORTALL TAKES 6.7% OF UNILIFE**

MARKET REPORT

The Australian stock market fell 0.51 percent on Friday October 4, 2013 with the S&P ASX 200 down 26.9 points to 5,208.0 points.

Nine of the Biotech Daily Top 40 stocks were up, 20 fell, six traded unchanged and five were untraded.

Optiscan was the best, up 0.8 cents or 12.9 percent to seven cents with 6,675 shares traded.

Neuren climbed five percent; Benitec and GI Dynamics were up more than four percent; Osprey and Patrys rose more than three percent; Genetic Technologies and Viralytics were up more than one percent; with CSL and Mesoblast up by less than one percent.

Avita led the falls, down one cent or 8.3 percent to 11 cents with 342,001 shares traded.

Cellmid, Living Cell and Psivida lost more than six percent; Atcor fell 5.4 percent; Anteo and Circadian were down more than three percent; Acrux, Alchemia, Allied Health, Clinuvel, Medical Developments, Phosphagenics, Prana, Prima and Sirtex shed more than two percent; Bionomics, QRX and Starpharma lost more than one percent; with Cochlear, Nanosonics and Resmed down by less than one percent.

SIRTEX MEDICAL

Sirtex says dose sales of its SIR-Spheres microspheres increased 4.1 percent for the three months to September 30, 2013, compared to the previous corresponding period. Last year, Sirtex said dose sales were up 37 percent for the three months to September 30, 2012 compared to the previous period (BD: Oct 4, 2012).

Sirtex did not disclose the values of the sales but, in August, said that total dose sales for the year to June 30, 2103 were 7,299 doses providing revenue of \$96,774,000 or an average of \$13,259 per dose (BD: Aug 15, 2013).

Today, Sirtex said it had recorded 37 consecutive quarters of positive growth with sales in the Americas up 6.6 per cent, the Asia-Pacific region up 10.2 per cent, but falling 5.1 percent in Europe, the Middle East and Africa.

Sirtex chief executive officer Gilman Wong said the quarter was "our second highest quarter in actual number of doses sold" but did not disclose the number of doses.

"However, when measured in percentage terms growth was lower than recent quarters," Mr Wong said.

Mr Wong said that sales in Europe, the Middle East and Africa were affected by the general European economic conditions and delays in reimbursement decisions in the UK. Sirtex fell 37 cents or 2.8 percent to \$12.80 with 300,509 shares traded.

CELLMID

Cellmid says it has received \$711,895 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Cellmid said the rebate related to research and development expenditure on its midkine technology in 2012-'13.

The company said that a further \$42,157 was expected from the Federal Government relating to research and development by its subsidiary Advangen International which develops and distributes hair loss products (BD: May 8, 28, 2013).

Cellmid said the funds would be used to advance its product development programs. Cellmid fell 0.2 cents or 6.7 percent to 2.8 cents with 10.4 million shares traded.

HEALTHLINX

Healthlinx says it has raised \$70,000 from four sophisticated investors to fund a notice of meeting and provide working capital.

The company said that 140,000,000 shares would be issued implying that the shares were cost 0.05 cents each.

The Appendix 3B New Issue Announcement filed to the ASX said the consideration was \$7,000, or 0.005 cents a share, and "in addition, the subscribers were required to make advances to the company of \$63,000 in total".

Healthlinx is subject to a deed of company arrangement and said the shareholder meeting would be asked to approve repayment of the advances made by the sponsors of the deed of company arrangement through an issue of shares.

The company said that the investor advance would be about 11.88 percent of its expanded issued capital.

Hall Chadwick administrators David Ross and Shanon Thomas were appointed as joint and several administrators of Healthlinx following the failure to commercialize its Ovplex ovarian cancer diagnostic (BD: May 7, 2103).

Healthlinx was suspended at 0.1 cents.

UNILIFE

Unilife chief executive officer Alan Shortall has increased his substantial shareholding from 4,992,643 US shares (5.0%) to 6,242,643 US shares (6.2%).

Mr Shortall said he also held 466,400 restricted US shares (0.5%).

Mr Shortall said that he exercised 1,250,000 options at \$1.98 each.

Each US share is equivalent to six Chess depositary interests (CDIs) meaning that the equivalent to 7,500,000 options were exercised at 33 cents each and Mr Shortall holds the equivalent of 40,254,258 CDIs.

Unilife fell 1.5 cents or 2.6 percent to 56 cents.